Linear 33 peptide capable of preventing and treating type 1 diabetes and having function of protecting pancreatic beta cells and application of linear 33 peptide

Abstract

The invention discloses a linear 33 peptide molecule which consists of a B epitope (10 peptide) of human dipeptidyl peptidase 4 and 23 peptide containing a Th2 epitope; serum of an animal immunized by33 peptide contains an antibody which has high price and can be specifically combined with DPP4; the antibody can inhibit the activity of the DPP4 and regulate immune rebalance trending to Th2; the 33 peptide is utilized to carry out subcutaneous immunological control or treat type 1 diabetic NOD mice and treat STZ-induced diabetic mice every 2 weeks, so that blood glucose is significantly controlled or reversed; the blood glucoses of the NOD mice are basically normal, GLP-1 and Th2 cytokines are significantly increased and glucagon and Th1 cytokines are significantly reduced, so that morbidity, death rate, multiple immune balances as well as uric acid, creatinine, blood lipid and oxidative stress indicators are remarkably improved, pancreatic inflammation is relieved, and the ability ofpancreas secreting insulin is significantly strengthened. The 33 peptide as well as vaccines and drugs prepared by using microorganisms, animals, plants and cell expression based on the 33 peptide areof great value in preventing and treating diabetes, especially in type 1 diabetes and complications and other diseases.

Description

technical field [0001] The invention relates to the related fields of immunity, pharmacy and medicine, and relates to a linear 33 peptide capable of preventing and treating type 1 diabetes and having the function of protecting pancreatic beta cells and its application in medicine and immunity. This 33-peptide is composed of a 10-peptide B-cell epitope of human dipeptidyl peptidase 4 (DPP4) and a 23-peptide containing a Th2 epitope. The serum of this 33-peptide immunized animal contains a high level of An antibody that can specifically bind to DPP4, which can inhibit DPP4 activity and regulate immune rebalancing towards Th2, is administered subcutaneously with this 33 peptide every 2 weeks to prevent or treat recognized type 1 diabetic NOD mice and treat STZ-induced Diabetic mice can significantly control or reverse blood sugar, significantly increase GLP-1 and Th2 cytokines, significantly reduce pancreatic glucagon and Th1 cytokines, and significantly change uric acid, creatin...

AI Technical Summary

Problems solved by technology

At present, a variety of DPP4 inhibitors, such as sitagliptin, saxagliptin and other chemical synthetic drugs, have been widely used in clinical practice. Although it has also been reported that DPP4 inhibitors are used in the treatment of type 1 diabetes (Type 1 diabetes mellitus, T1DM), but Because it is a chemical drug, it is often accompanied by long-term side effects, especially in middle-aged and elderly people who suffer from secretory and metabolic diseases accompanied by hypertension, hyperlipidemia and hyperglycemia. Long-term poor control leads to kidney damage

Images